Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

Phase 1

Completed

Conditions: RSV Infection

Interventions: Drug: EDP-938
Drug: Itraconazole
Drug: Rifampin
Drug: Quinidine

First Posted Date: 2018-11-28

Last Posted Date: 2019-06-14

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 72

Registration Number: NCT03755778

Locations: 🇺🇸
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

Phase 1

Completed

Conditions: Drug-drug Interaction

Interventions: Drug: tucatinib
Drug: repaglinide
Drug: itraconazole
Drug: rifampin
Drug: gemfibrozil
Drug: digoxin
Drug: tolbutamide
Drug: midazolam

First Posted Date: 2018-10-29

Last Posted Date: 2019-12-18

Lead Sponsor: Seagen Inc.

Target Recruit Count: 116

Registration Number: NCT03723395

Locations: 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States

An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986278
Drug: Rifampin

First Posted Date: 2018-10-19

Last Posted Date: 2019-06-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 39

Registration Number: NCT03712540

Locations: 🇺🇸
PRA Health Science KK, Lenexa, Kansas, United States

Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs

Phase 1

Completed

Conditions: HIV-1-infection

Interventions: Drug: Elpida®
Drug: Levonorgestrel+Ethinylestradiol
Drug: Clarithromycin
Drug: Rifampin
Drug: Rifabutin
Drug: Omeprazole
Drug: Atorvastatin

First Posted Date: 2018-10-17

Last Posted Date: 2022-01-26

Lead Sponsor: Viriom

Target Recruit Count: 56

Registration Number: NCT03709355

Locations: 🇷🇺
Central Clinical City Hospital, Reutov, Moscow Region, Russian Federation

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

Phase 2

Active, not recruiting

Conditions: Nontuberculous Mycobacterium Infection
Mycobacterium Avium Complex

Interventions: Drug: Azithromycin
Drug: Ethambutol
Drug: Rifampin

First Posted Date: 2018-09-14

Last Posted Date: 2024-12-04

Lead Sponsor: Kevin Winthrop

Target Recruit Count: 474

Registration Number: NCT03672630

Locations: 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

and more 23 locations